
NYSEHealthcareMedical - Instruments & Supplies
最新数据
US$364.56
−US$1.925 · -0.53%
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
常规交易时段
US$364.22
−US$2.26 · -0.62%
盘中时间采用ET。市场数据可能有所延迟。
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
日内区间
当前US$364.22
52周区间
当前US$364.22
盘中时间采用ET。市场数据可能有所延迟。
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
日内区间
当前US$364.22
52周区间
当前US$364.22
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 30.74亿 USD | 28.93亿 USD | 29.51亿 USD | 28.86亿 USD | 28.31亿 USD |
| 销货成本 | 19.7亿 USD | 18.91亿 USD | 18.18亿 USD | 17.47亿 USD | 16.57亿 USD |
| 毛利 | 11.03亿 USD | 10.02亿 USD | 11.33亿 USD | 11.39亿 USD | 11.73亿 USD |
| 研究与开发 | 7430万 USD | 6910万 USD | 6840万 USD | 5850万 USD | 5280万 USD |
| 销售、一般及管理费用 | 3.93亿 USD | 3.39亿 USD | 3.53亿 USD | 3.17亿 USD | 3.62亿 USD |
| 营业费用 | 4.86亿 USD | 4.08亿 USD | 4.22亿 USD | 3.75亿 USD | 4.15亿 USD |
| 利息收入 | 1770万 USD | 1960万 USD | 2800万 USD | 510万 USD | 100万 USD |
| 利息支出 | 60万 USD | 290万 USD | 880万 USD | 760万 USD | 850万 USD |
| 折旧和摊销 | 1.71亿 USD | 1.55亿 USD | 1.37亿 USD | 1.21亿 USD | 1.22亿 USD |
| 营业利润 | 6.17亿 USD | 5.95亿 USD | 7.11亿 USD | 7.64亿 USD | 7.59亿 USD |
| 净利润 | 4.94亿 USD | 4.93亿 USD | 5.93亿 USD | 5.86亿 USD | 6.62亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$419.5
上涨空间 15.18%年度分割调整后的每股现金分配。
US$0.85
2025年(完整年度)+23.2% 自从 2021
2026年(部分年度):US$0.66
US$0.69
2,021
US$0.73
2,022
US$0.77
2,023
US$0.81
2,024
US$0.85
2,025
US$0.66
2,026*
* 在现有股息历史记录中,该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月29日 | US$0.22Quarterly | 2026年7月29日 | 2026年8月5日 |
股息 | 2026年4月29日 | US$0.22Quarterly | 2026年4月29日 | 2026年5月6日 |
股息 | 2026年1月28日 | US$0.22Quarterly | 2026年1月28日 | 2026年2月4日 |
股息 | 2025年11月12日 | US$0.22Quarterly | 2025年11月12日 | 2025年11月19日 |
股息 | 2025年7月30日 | US$0.21Quarterly | 2025年7月30日 | 2025年8月6日 |
股息 | 2025年4月30日 | US$0.21Quarterly | 2025年4月30日 | 2025年5月7日 |
除息 2026年7月29日
US$0.22
Quarterly
2026年7月29日登记 · 支付日 2026年8月5日
除息 2026年4月29日
US$0.22
Quarterly
2026年4月29日登记 · 支付日 2026年5月6日
除息 2026年1月28日
US$0.22
Quarterly
2026年1月28日登记 · 支付日 2026年2月4日
除息 2025年11月12日
US$0.22
Quarterly
2025年11月12日登记 · 支付日 2025年11月19日
除息 2025年7月30日
US$0.21
Quarterly
2025年7月30日登记 · 支付日 2025年8月6日
除息 2025年4月30日
US$0.21
Quarterly
2025年4月30日登记 · 支付日 2025年5月7日
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T500.17亿0.04%129.41万亿 JPY0.09%JP¥122,700-0.57%
Vanguard Morningstar Total Stock Market ETFVTI7.66亿0.03%2.3万亿 USD0.03%US$378.7-0.61%
Vanguard S&P 500 ETFVOO6.4亿0.04%1.8万亿 USD0.03%US$709.59-0.66%
Vanguard Morningstar Mid-Cap ETFVO5.21亿0.23%2264亿 USD0.03%US$80.275+0.17%
iShares Core S&P 500 ETFIVV3.43亿0.04%8996.25亿 USD0.03%US$775.37-0.67%
Vanguard Morningstar Growth ETFVUG3.18亿0.08%3846亿 USD0.03%US$91.06-1.47%
State Street SPDR S&P 500 ETFSPY3.16亿0.04%8190.39亿 USD0.09%US$771.96-0.68%
Invesco S&P 500 Equal Weight ETFRSP2.13亿0.22%964.72亿 USD0.20%US$211.5+0.42%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
Vanguard Morningstar Growth ETFVUG
State Street SPDR S&P 500 ETFSPY
Invesco S&P 500 Equal Weight ETFRSPAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。